Project Details
Description (abstract)
The Rare Cancers Research Group explores the molecular mechanisms associated with cancerogenesis and tumour progression focusing on rare cancers. We aim to identify novel cancer-specific biomarkers and ultimately improve diagnostics and therapies. We are determined to pave the way towards precision medicine to effectively treat rare cancers.
| Acronym | RaCaRe |
|---|---|
| Status | Active |
| Effective start/end date | 01/01/2018 → … |
Funding
- Sarcoma Foundation of America: €41,260.00
- Relanderin säätiö: €50,000.00
- Mary ja Georg C. Ehrnroothin säätiö: €20,000.00
- Suomen tiedeseura: €12,000.00
Projects
- 1 Finished
-
Uudet ennustetekijät ja lääkekohteet pahanlaatuisissa liposarkoomissa
Sihto, H. (Project manager), Jaatinen, J. K. (Participant), O'Dell, P. (Participant) & Salmikangas, S. I. (Participant)
01/01/2017 → 31/12/2019
Project: University of Helsinki Three-Year Research Project
Research output
- 26 Article
-
Antiviral regulator TRIM25 as a prognostic marker of better survival in Merkel cell carcinoma: Association with MCPyV status
Fagerstedt, K. W., Kilpinen, S., Arola, J., Sundqvist, B. Z., Böhling, T., Andersson, L. C. & Sihto, H., 14 Feb 2026, In: International Journal of Cancer. n/a, n/a, 11 p., PMID 42124.Research output: Contribution to journal › Article › Scientific › peer-review
Open AccessFile -
Clinicopathological comparison of eccrine poroma and porocarcinoma: Ki-67 index is not a decisive factor
Meriläinen, A.-S., Sihto, H., Isola, J. & Koljonen, V., 30 May 2025, In: PLoS One. 20, 5, 9 p., e0324975.Research output: Contribution to journal › Article › Scientific › peer-review
Open AccessFile -
Fibroblast growth factor receptor expression in hemangioblastomas: A novel therapeutic target
Puttonen, M., Tynninen, O., Salmikangas, S., Vesterinen, T., Sihto, H. & Böhling, T., 20 May 2025, In: PLoS One. 20, 5, 16 p., e0323979.Research output: Contribution to journal › Article › Scientific › peer-review
Open AccessFile